Progyny (PGNY) Expected to Announce Earnings on Thursday

Progyny (NASDAQ:PGNY) is anticipated to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.38 per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:45 PM ET.

Progyny Price Performance

PGNY stock opened at $20.36 on Thursday. The company has a market capitalization of $1.76 billion, a P/E ratio of 32.32, a price-to-earnings-growth ratio of 1.29 and a beta of 0.96. Progyny has a 12 month low of $17.98 and a 12 month high of $28.75. The firm’s fifty day simple moving average is $24.68 and its 200-day simple moving average is $23.21.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Citigroup raised shares of Progyny to an “outperform” rating in a report on Tuesday, January 20th. KeyCorp upped their target price on Progyny from $30.00 to $32.00 and gave the stock an “overweight” rating in a research note on Thursday, January 8th. Barclays initiated coverage on Progyny in a report on Monday, December 8th. They set an “overweight” rating and a $29.00 target price on the stock. BTIG Research restated a “buy” rating on shares of Progyny in a research report on Wednesday, January 21st. Finally, Zacks Research cut shares of Progyny from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Eight analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Progyny has an average rating of “Moderate Buy” and an average target price of $29.80.

Institutional Trading of Progyny

A number of hedge funds and other institutional investors have recently modified their holdings of PGNY. Wellington Management Group LLP boosted its position in shares of Progyny by 260.9% during the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after acquiring an additional 1,621,688 shares during the last quarter. Loomis Sayles & Co. L P purchased a new stake in shares of Progyny during the 4th quarter valued at approximately $19,917,000. Ameriprise Financial Inc. lifted its holdings in Progyny by 37.6% in the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after acquiring an additional 545,431 shares during the last quarter. Norges Bank purchased a new position in Progyny in the fourth quarter worth approximately $10,167,000. Finally, Qube Research & Technologies Ltd increased its stake in Progyny by 161.6% during the third quarter. Qube Research & Technologies Ltd now owns 457,015 shares of the company’s stock worth $9,835,000 after acquiring an additional 282,322 shares during the last quarter. 94.93% of the stock is owned by institutional investors and hedge funds.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.